Specialty Pharmacy

Top news of the day from across the health care landscape.

This approval expands tezacaftor/ivacaftor’s indication to include patients ages 6 and older with cystic fibrosis who have certain genetic mutations.

Patients with multiple sclerosis who switched disease-modifying treatments at least twice had a higher relative risk of developing cancer.

Officials with the FDA have approved Allergan’s supplemental biologics application (sBLA) for onabotulinumtoxinA (Botox) for the treatment of children, ages 2 to 17 years, with upper limb spasticity.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

2019 Pharmacy Quality Alliance Annual Meeting included discussions on measures to improve medication services and how pharmacists can play a larger role in the multidisciplinary care team.

Top news of the day from across the health care landscape.

Investigators find visuals more effective than language when prompting people to self-screen for melanoma.

African Americans can frequently experience barriers in seeking out lifesaving clinical trials for cancer treatments.

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) is indicated for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least 1 prior line of therapy.

Top news of the day from across the health care landscape.

A new study finds that artificial intelligence diagnoses rare diseases quicker and with more accuracy.

Officials with the FDA today approved liraglutide (Victoza, Novo Nordisk) injection for treatment of pediatric patients age 10 years or older with type 2 diabetes (T2D).

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.

Top news of the day from across the health care landscape.

At the Asembia Specialty Pharmacy Summit 2019, a panel of experts educated audience members about chronic inflammatory demyelinating polyneuropathy.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The approval of Amgen’s trastuzumab-anns, the fifth biosimilar to Herceptin, marks the twentieth biosimilar approved by the FDA.

Investigators aim to develop cellular models to mimic the biological processes responsible for the onset of multiple sclerosis.

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

Top news of the day from across the health care landscape.